路透哥本哈根4月22日 - 瑞典生物技术公司Biotage BIOT.ST周二表示，KKR已对这家瑞典生物技术公司提出现金收购要约，估值约为116亿瑞典克朗(12.2亿美元)。
每股 145 克朗的收购价与 4 月 17 日的收盘价相比溢价 60.1%。
Biotage 公司在一份声明中说，公司董事会一致建议股东接受收购要约。
由 KKR 控制的 Gamma Biosciences 公司是该公司最大的股东，持有 17% 的股份。
(1 美元 = 9.5059 瑞典克朗)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.